Kad­mon sticks a $100M toe in chilly mar­ket wa­ters

Are we see­ing a re­an­i­ma­tion of the biotech IPO mar­ket? The in­vest­ment com­mu­ni­ty cer­tain­ly hopes so, and now Kad­mon will help put it to a test.

The biotech, a brain­child of ex-CEO and founder Sam Wak­sal, has laid out terms for its IPO, look­ing to sell 5.5 mil­lion shares with­in a range of $16 to $20 per. It’s an­oth­er in­sid­er-heavy deal, with in­vestors com­mit­ting to buy up to 40% of the shares to help make it a suc­cess. And the com­pa­ny hopes to raise around $100 mil­lion in the ef­fort.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.